Skip to main content

Table 4 Base case results of the alternative scenarios

From: Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study

Strategy Cost Δ Cost QALY Δ QALY ICER
Standard Care 33369.9   0.7673   
Remdesivir 32409.7 -960.2 0.7848 0.01748 Dominant
(Assuming mortality benefit)      
Remdesivir 35709.9 2340 0.7734 0.0061 384412.8
(Assuming only fixed costs)      
Remdesivir 28861.2 -4330.7 0.7734 0.0061 Dominant
(Assuming only cost per day)      
Strategy Cost Δ Cost   Life Saved ICER
Standard Care 29,686,258    ref.  
Dexamethasone 29,673,208 13050   42 313.79